Ketesse (Dexketoprofen Trometamol) is generally considered relevant for managing symptoms related to physical discomfort, primarily those of mild to moderate intensity, and is applied across domains where additional symptomatic support is needed. Its use is applicable within clinical settings that involve acute or disruptive symptom patterns, and is considered relevant in contexts involving heightened systemic burden.

Common uses of this medication include providing relief for musculoskeletal pain, acute pain following dental procedures, and discomfort associated with primary dysmenorrhoea (menstrual pain).

“Ketesse may provide support to the patient during difficult episodes by helping to ease discomfort.”

---

Acute Symptom Management and Relief

The medication may assist with easing symptoms that create noticeable physiological strain arising from soft tissue injuries, post-procedural discomfort, and inflammatory or irritative states. It is commonly used across conditions characterized by periods of heightened symptoms such as renal colic. This use supports general well-being during symptomatic phases that interfere with routine activities.

---

Quick Fact

Quick Fact: Relevant for Acute Musculoskeletal Pain and Episodic Visceral Discomfort

Regulatory References

1. Summary of Product Characteristics (SmPC) from the Medicines Authority of Malta

Who Can and Cannot Use Ketesse?

The eligibility for using Ketesse (dexketoprofen) is strictly determined by regulatory bodies, with use permitted only in adults (18 years and older). Safety and efficacy have not been established in children and adolescents, and its use is therefore not recommended.

Ketesse is subject to specific absolute contraindications based on pre-existing health conditions and physiological states. Use is strictly prohibited for patients with:

• Gastrointestinal Risk: Active peptic ulcer, gastrointestinal bleeding, perforation, or a history of GI bleeding related to previous NSAID use.
• Organ Function Impairment: Severe heart failure, moderate to severe renal dysfunction (creatinine clearance leq 59 mL/min), or severely impaired hepatic function (Child-Pugh score 10 –15).
• Hypersensitivity: Known reactions to dexketoprofen, other NSAIDs, or prior NSAID-induced asthma, bronchospasm, or urticaria.

Conditional Eligibility

Population	Eligibility Status (as per label)
Third Trimester Pregnancy	Contraindicated (Prohibited)
First/Second Trimester Pregnancy	Not Recommended (Unless clearly necessary)
Breastfeeding	Not Recommended
Older Adults	Use with caution (Lower starting dose advised)

Patients with mild renal or mild hepatic impairment are eligible only under conditional circumstances, requiring dose reduction and close medical supervision.

Interactions with other medicines and products

Category	Official Regulatory Statement
Contraindicated Combinations	The injectable solution is contraindicated for neuraxial (intrathecal or epidural) administration due to the presence of ethanol in the formulation.
Pharmacodynamic Risk	Co-administration with Oral Corticosteroids, Anticoagulants (e.g., Warfarin, Heparins), Anti-platelet agents, and Selective Serotonin-Reuptake Inhibitors (SSRIs) carries an increased risk of gastrointestinal ulceration and bleeding.
Exposure Modification	Lithium and Methotrexate (particularly at higher doses) may experience increased plasma concentrations due to reduced renal clearance caused by this medicine.
Renal Function	Use with Diuretics or agents affecting renal function (e.g., ACE inhibitors, ARBs) carries a heightened risk of nephrotoxicity and may reduce the therapeutic effect of the co-administered drug.

Regulatory warnings state that use with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to the additive risk of adverse effects. For the oral tablets, if taken for acute pain relief, administration is recommended at least 30 minutes before meals to ensure a faster absorption rate. Elderly patients are noted in labeling to have an increased risk for adverse effects, especially gastrointestinal bleeding, when receiving concomitant medications that heighten GI risk.

Dexketoprofen Trometamol works by modulating key enzymatic pathways responsible for producing eicosanoid mediators. Its mechanism is defined by its structure as the pharmacologically active S-(+)-enantiomer.

Inhibition of Cyclooxygenase Enzymes

The drug’s action involves the competitive inhibition of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). This interaction prevents the initial step in the conversion of arachidonic acid, a fatty acid, into short-lived precursors. This action limits signaling sequences that lead to downstream physiological effects, specifically reducing the synthesis of prostaglandins and thromboxanes.

Regulation of Nociceptive and Thermoregulatory Pathways

The functional consequence of reduced prostaglandin levels is the modulation of peripheral nociceptor sensitization, altering the signaling threshold of sensory neurons. In parallel, the mechanism also supports the regulation of central processes by limiting prostaglandin production in the hypothalamus, which is the physiological region that controls the body's temperature set point. This dual activity modifies the output of the peripheral nociceptive system and the hypothalamic thermoregulatory center.

How Ketesse Is Used: Administration Guidelines

Ketesse (Dexketoprofen Trometamol) is administered according to specific, documented instructions to ensure proper use across its available forms. These instructions define the route, required dose, frequency, and time limitations.

---

Administration Routes and Dosing

The medicine is available for both oral and parenteral (Intramuscular or Intravenous) administration. The single oral dose is typically 25 mg of dexketoprofen, taken up to three times daily, with a maximum total daily limit of 75 mg. For acute, severe pain, the parenteral dose is 50 mg, which may be repeated at 6 or 8-hour intervals, not to exceed a total daily dose of 150 mg.

---

Procedural and Time Constraints

Instruction Domain	Guideline
Timing in Relation to Meals	Oral doses (tablets/sachets) should be taken at least 30 minutes before meals to optimize drug absorption.
Parenteral Duration Limit	The use of the injectable form (IM/IV) is restricted to a maximum of two consecutive days (48 hours) for acute pain management.
IV Administration	Must be given as a slow intravenous infusion over a period of 10 to 30 minutes, or as a slow, deep IM injection.
Population Adjustment	Treatment for older adults or patients with mild renal or hepatic impairment should be initiated at a reduced total daily dose, typically not exceeding 50 mg.

The protocol mandates short-term use, especially for the injectable form, and requires specific dose reductions based on the patient population.

Research evidence / Overview of studies for Ketesse

The available research evidence for Ketesse (Dexketoprofen Trometamol) consists primarily of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. This overview describes what the research has explored and what findings have been reported, focusing on study patterns and limitations without offering personal advice or clinical instructions.

---

Evidence for Acute Pain Management

Research primarily consists of short-term, single-dose Randomized Controlled Trials (RCTs) applied in settings like dental and post-operative pain. These trials compared the medicine against both placebo and active comparator treatments. Research examined changes in patient-reported discomfort and monitored time-based metrics. Findings described patterns where measured outcomes in the group receiving the medicine differed from those receiving a placebo. However, the evidence is mainly restricted to single-dose administration or very short courses, meaning that research does not fully characterize discomfort management required for longer-duration recovery.

Research Findings in Musculoskeletal and Visceral Pain

The medicine was studied in conditions such as acute musculoskeletal disorders (e.g., strains) and acute visceral pain (e.g., renal colic), using both oral and injectable forms. Studies monitored changes in pain intensity scores and, in post-operative research settings, explored an opioid-sparing effect (a reduction in the amount of other strong pain relief used). Research conducted on acute menstrual pain (dysmenorrhoea) similarly explored short-term symptom changes and highlighted measured changes in discomfort. For most of these conditions, follow-up durations were limited (e.g., up to three weeks), meaning that there is limited information for long-term outcomes.

Unresolved Questions and Research Gaps

The majority of clinical trials focus on acute pain conditions, meaning that data for long-term outcomes and the patterns of symptom stability over extended periods are not fully established. While the medicine was studied in generally healthy adult populations, data for certain groups, such as those with multiple pre-existing medical conditions (comorbidities), remain insufficient. Furthermore, the diversity of comparators and conditions studied means that the characteristics of evidence vary across studies, and results apply only to the specific populations studied.

Key Studies & References

1. Summary of Product Characteristics (SmPC) for KETESSE 50 mg/2ml Solution for injection (Regulatory Document)
2. Systematic review of dexketoprofen in acute and chronic pain (Health Technology Assessment)

Common questions about Ketesse (FAQ)

---

Q: How quickly should I expect to feel pain relief after taking Ketesse?

Official product information indicates that the active ingredient in Ketesse is rapidly absorbed into the bloodstream. The highest concentration of the medicine in the blood is typically reached within 30 minutes after taking the oral dose. The rapid absorption is consistent with the goal of providing timely relief.

---

Q: How long does the pain relief from Ketesse usually last?

The recommended dose, according to regulatory documents, is typically taken every eight hours. This dosing interval aligns with the pharmaceutical profile of the drug. The actual duration of relief can vary among individuals.

---

Q: What happens if I take Ketesse for more than a few days?

Ketesse oral tablets are intended only for short-term, symptomatic use. Regulatory warnings state that prolonged use increases the potential risk of serious side effects, particularly affecting the gastrointestinal tract. Official documentation notes that the product is intended only for short-term, symptomatic use.

---

Q: Is it true that Ketesse is absorbed faster than standard ketoprofen?

Official documentation describes Ketesse as the S-(+)-enantiomer, a specific structure of the active substance. This targeted composition is associated with efficient therapeutic action and a rapid rate of absorption. This targeted composition is noted in pharmacological information.

---

Q: Can Ketesse affect my ability to drive or operate machinery?

Official product information states that the ability to drive and use machines may be affected. This caution is issued because uncommon side effects like dizziness, vertigo, or drowsiness (somnolence) are possible when taking Ketesse.

---

Q: Can I take an antacid medication shortly after taking Ketesse?

Antacids are not explicitly listed in the major interaction tables for Ketesse. However, protective agents, such as proton pump inhibitors, may sometimes be recommended for patients with a higher risk of gastrointestinal issues.

---

Q: Do other medications like antidepressants interact with Ketesse?

Yes, regulatory warnings specify an interaction with certain types of antidepressants. Co-administration of Ketesse with Selective Serotonin Re-uptake Inhibitors (SSRIs) carries an increased risk of gastrointestinal ulceration and bleeding.

---

Q: How is Ketesse eliminated from the body?

Official dosing guidelines and contraindications provide an indication about elimination. Specific dose adjustments and restrictions are in place for patients with impaired kidney (renal) or liver (hepatic) function. This shows that the liver and kidneys are the primary organs responsible for metabolizing the drug and eliminating it from the body.

---

Q: What is the longest period of time you can safely take Ketesse?

Regulatory documents state that the medicine is intended for short-term use. For the oral tablets, treatment should be limited only to the symptomatic period. The injectable solution has a clear limit, restricted to a maximum of two consecutive days of use.

---

Q: Are there any specific warning signs of a severe side effect from Ketesse?

Official warnings highlight the possibility of serious adverse events. Warnings note that signs of gastrointestinal bleeding include vomiting blood or passing black stools. Patients are also alerted to symptoms potentially related to cardiovascular risks, such as unexpected chest pain.

---

Q: Is it normal to feel a burning sensation in the stomach after taking Ketesse?

Gastrointestinal side effects are common with this class of medicine. While 'stomach pain' and 'dyspepsia' (indigestion) are frequently reported, official sources also list gastritis (inflammation of the stomach lining) as an uncommon effect, which can manifest as a burning sensation.

---

Q: Does Ketesse interact with alcohol?

Regulatory documents caution that ingestion of alcohol may increase the likelihood of experiencing gastrointestinal adverse effects associated with the medicine. This caution is because alcohol may increase the likelihood of experiencing gastrointestinal adverse effects.

---

Q: Is there any concern about taking Ketesse with other pain relievers that are NOT NSAIDs?

Official interaction warnings specifically advise against co-administration with other NSAIDs (non-steroidal anti-inflammatory drugs) due to an additive risk of adverse effects. Interactions with non-NSAID pain relievers are not listed as specific contraindications.

Storage and Disposal of Ketesse: Regulatory Requirements

Ketesse (dexketoprofen trometamol) must be stored and handled according to official regulatory specifications to maintain quality and prevent harm.

Storage Conditions

Storage Requirement	Specification
Child Safety	Keep out of the sight and reach of children.
Container	Store in the original package (blister or ampoule).
Protection	The product must be protected from light.

Film-coated tablets do not require special temperature storage conditions. The injectable solution, if diluted, is stable for 24 hours at 2-8°C when protected from light, but must be used immediately otherwise.

Disposal

Do not use the medicine past the expiry date (EXP). Unused or expired Ketesse must not be thrown away via wastewater or household waste. Disposal must be performed according to local requirements, typically by returning the product to a pharmacy.